Halozyme Therapeutics Company Profile

07:47 EDT 21st September 2018 | BioPortfolio

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine


Phone: 858.794.8889

News Articles [736 Associated News Articles listed on BioPortfolio]

Halozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per Share

Analysts predict that Halozyme Therapeutics, Inc. will post earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Halozyme Th...

Halozyme Therapeutics, Inc. (HALO) Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada Halozyme Therapeutics, Inc. (HALO) today announced that Roche has received approval from Health Canada fo...

Halozyme Therapeutics, Inc. (HALO) Appoints Bernadette Connaughton To Board Of Directors

Halozyme Appoints Bernadette Connaughton To Board Of Directors Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the ap...

Halozyme, Edico CEOs Among San Diego’s Entrepreneurs of the Year

Helen Torley, who was highlighted in 2016 as the only female CEO of a public life sciences company in San Diego, was recognized last week for her operational excellence at Halozyme Therapeutics (NASDA...

Halozyme Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides

Halozyme Therapeutics, Inc. 2018 Q2 - Results - Earnings Call Slides

Halozyme Identifies Plasma Biomarkers as Potential Predictors of Survival in Pancreatic Cancer

SAN DIEGO, June 1, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present data evaluating ce...

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript

PubMed Articles [434 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [154 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1255 Associated Companies listed on BioPortfolio]

Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery m...

Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalm...

Baxter International Inc. and Halozyme Therapeutics, Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cance...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Halozyme Therapeutics" on BioPortfolio

We have published hundreds of Halozyme Therapeutics news stories on BioPortfolio along with dozens of Halozyme Therapeutics Clinical Trials and PubMed Articles about Halozyme Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Halozyme Therapeutics Companies in our database. You can also find out about relevant Halozyme Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record